Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 3/20 | 0.46 |
| ▸ | ACHE | P22303 | 2/20 | 0.45 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.43 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | FAAH | O00519 | 1/20 | 0.42 |
| ▸ | BCHE | P06276 | 1/20 | 0.42 |
| ▸ | CASR | P41180 | 2/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL335816 | 1.00 | AOC3 (0.46) | AOC3ACHETAAR1TRPM8L3MBTL1 | |
| SCHEMBL18297336 | 0.88 | ACHE (0.53) | AOC3ACHETAAR1TRPM8L3MBTL1 | |
| SCHEMBL334241 | 0.82 | ALOX5 (0.43) | AOC3ACHETAAR1SLC6A4 | |
| SCHEMBL335068 | 0.81 | AOC3 (0.40) | AOC3ACHETAAR1TRPM8KDM4E | |
| SCHEMBL335051 | 0.79 | AOC3 (0.41) | AOC3TAAR1TRPM8SLC6A2SLC6A4 | |
| SCHEMBL1132949 | 0.79 | OPRK1 (0.53) | ACHETAAR1KDM4ETSHR | |
| SCHEMBL334403 | 0.79 | AOC3 (0.41) | AOC3TAAR1SLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL31500336 | 0.78 | AOC3 (0.40) | AOC3TAAR1TRPM8SLC6A2SLC6A4 | |
| SCHEMBL334856 | 0.78 | GBA1 (0.36) | ACHEKDM4ETSHRFAAHBCHE | |
| SCHEMBL10243851 | 0.78 | MTNR1A (0.47) | ACHETRPM8FAAHBCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8097708-B2 | 10a-Azalide compound | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-20090281292-A1 | 10a-Azalide Compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2009-11-12 | — | — | US | disclosed |
| EP-1985620-A1 | 10a-AZALIDE COMPOUND | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2008-10-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281292-A1 | 10a-Azalide Compound | IL17A, AZI2, HDAC9 | AOC3 4508/4885ACHE 1324/4885TAAR1 4408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.